Salute e Benessere

HKBU develops new approach for accurate and efficient inspection of…

More accurate and efficient test in need More accurate and efficient test in need Sulfur treatment, including sulfur fumigation and the addition of sulfites, is a common preservation method employed in the food and Chinese herbal medicinal industries. However, excessive consumption of preservative sulfites in food and Chinese herbal medicinal products can lead to respiratory symptoms and compromised nutritional value and safety. Currently, sulfite test is the most commonly used...
PR Newswire
29/07/2024

IM Cannabis Receives NASDAQ Notification of Regaining Compliance with Nasdaq's…

About IM Cannabis Corp. About IM Cannabis Corp. IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients inIsraelandGermany, two of the largest medical cannabis markets. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments,...
PR Newswire
29/07/2024

Endo Releases Annual Corporate Responsibility Report

The 2023 report details efforts and progress across four pillars. Here are select 2023 highlights: The 2023 report details efforts and progress across four pillars. Here are select 2023 highlights: Business Practices: Team: Customers: World: Read the full report atendo.com. About EndoEndo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver...
PR Newswire
29/07/2024

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 29 July 2024– On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the…
Nasdaq GlobeNewswire
29/07/2024

EXPOSURE TO WILDFIRE SMOKE GREATLY RAISES RISK OF DEMENTIA DIAGNOSIS

Wildfire smoke, motor vehicles and factories all emit a type of air pollution called fine particulate matter (PM2.5). This is a microscopic mixture of solid and liquid droplets in the air that are 30 times smaller than the width of an average human hair. Researchers found that the risk of dementia diagnosis due to exposure to PM2.5 in wildfire smoke was notably stronger — even with less exposure — than the risk due to the other sources of PM2.5 air pollution. Exposure to non-wildfire PM2.5…
PR Newswire
29/07/2024

Tilray's Aphria RX Receives Cannabis Trading License in Germany, Significantly…

"This milestone of Aphria RX obtaining both its new cultivation license as well as its trading license further expands Tilray's leadership in medical cannabis research, cultivation, production and distribution in Germany and once again proves our commitment to be one of the most responsible, trusted and market leading cannabis companies in the world with a portfolio of innovative and high-quality products that address the needs of patients. We remain dedicated to advocating for…
Nasdaq GlobeNewswire
29/07/2024

Prescription Digital Therapeutics (PDT) Market Expected to Grow at a CAGR of…

Prescription Digital Therapeutics (PDT) represent a new category of medical treatments that utilize software applications to deliver therapeutic interventions under the supervision of healthcare providers. Prescription digital drugs are created by combining biology and technology. Artificial intelligence, various algorithms, and virtual reality were used in the creation of these therapeutic aids. Digital therapies, or prescription PDTs, are a relatively new class of medications. PDTs function as…
PR Newswire
29/07/2024

Hepatocyte Growth Factors (HGFs) Market to Reach USD 141 Million by 2034: Rising…

Hepatocyte growth factors (HGFs) are amongst the potent mitogens for hepatocytes and various other cells that include keratinocytes and melanocytes apart from epithelial and endothelial cells. HGFs are also ligands for receptors encoded by c-met proto-oncogene. Hepatocyte growth factors (HGFs) are amongst the potent mitogens for hepatocytes and various other cells that include keratinocytes and melanocytes apart from epithelial and endothelial cells. HGFs are also ligands for receptors…
PR Newswire
29/07/2024

AliveDx Receives IVDR CE Mark for Groundbreaking Microarray Immunoassay in…

The multiplex immunoassay microarray technology marks a significant advancement in diagnostics by enabling simultaneous testing for multiple conditions. This approach streamlines the identification process, simplifies laboratory workflows, and reduces the hands-on time required with singleplex methods. As a result, both laboratories and clinicians save valuable time and can detect and rule out various conditions more efficiently. For patients sensitized to multiple allergens (polysensitized)…
PR Newswire
29/07/2024

Nucleic Acid Aptamers Market to Reach USD 1.2 Billion by 2034: Unique…

Since their discovery in the 1990s, several attempts have been made to utilize aptamers as clinical agents for diseases such as AIDS and macular degeneration. It is important to note that the first aptamer-based therapeutic to receive U.S. FDA approval was Macugen (Pegaptanib), that acts as a selective antagonist of vascular endothelial growth factor (VEGF) and is indicated for the treatment of patients suffering from neovascular age-related macular degeneration. Since their discovery in the...
PR Newswire
29/07/2024

Invitation to Immunovia's Q2 presentation

Telephone numbers and webcastCall any of the numbers below to participate via telephone. Please dial in a few minutes before the presentation starts. Telephone numbers and webcastCall any of the numbers below to participate via telephone. Please dial in a few minutes before the presentation starts. Sweden : +46 (0)8 5051 0031United Kingdom : +44 (0) 207 107 06 13United States : +1 (1) 631 570 56 13 Link to the webcast: ...
PR Newswire
29/07/2024

Liposomal Supplements Market Anticipated to Achieve US$ 741.0 million Valuation…

Advancement of technology in the production of liposomes and encapsulation techniques are aspects which have increased the growth in the market. These new developments let one formulate stable, potent, and targeted supplements that are luring investments from new entrants as well as established companies in the nutraceutical sector. Advancement of technology in the production of liposomes and encapsulation techniques are aspects which have increased the growth in the market. These new...
PR Newswire
29/07/2024

CHMP adopts positive opinion recommending approval of new and expanded…

The CHMP positive opinion is based on the EFFISAYIL® 2 trial, which showed that no flares were observed after week 4 of SPEVIGO® administered subcutaneously. During the 48-week trial, an 84% reduction of the risk of GPP flares was observed.GPP is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin flares and systemic symptoms, such as fever, pain, and fatigue.SPEVIGO® is currently approved in 51 countries for treatment of GPP flares, and the CHMP opinion...
Nasdaq GlobeNewswire
29/07/2024

EssilorLuxottica announces launch of share buyback program

EssilorLuxottica announces launch of share buyback programParis, France (July 29, 2024 – 08:00 am CEST)– EssilorLuxottica announces the launch of its share buyback program reflecting the Group's confidence in its value creation and long-term prospects.With a view to implementing this share buyback program, EssilorLuxottica has granted a mandate to an investment services provider for the purchase of up to 4,000,000 EssilorLuxottica shares, depending on market conditions, over a period...
Nasdaq GlobeNewswire
29/07/2024

DBV Technologies to Report Second Quarter 2024 Financial Results and Business…

DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, July 30 th, at 5:30 p.m. ET to review its second quarter 2024 financial results and provide a business update.Interested participants may access this call via the...
Nasdaq GlobeNewswire
29/07/2024

BerGenBio Announces Selection of 2nd Dose in Phase 2a First Line STK11m…

BERGEN, Norway, July 29, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that the independent Data and Safety Monitoring Board (DSMB) for BerGenBio's Phase 1b/2a BGBC016 study confirmed acceptable safety at the highest dose tested in the Phase 1b. As a result, the DSMB also recommended that under the study protocol, no additional patients will be required…
PR Newswire
29/07/2024

Roche closes acquisition of LumiraDx's Point of Care technology to expand access…

The acquisition of LumiraDx's Point of Care technology received all required antitrust and regulatory clearances.LumiraDx's transformative Point of Care solution will complement Roche's diagnostics portfolio across Clinical Chemistry, Immunochemistry, Coagulation and Molecular, and across multiple disease areas.By integrating LumiraDx, Roche will further its ambition to deliver decentralised solutions that expand global access to testing in primary care settings worldwide.Basel,...
Nasdaq GlobeNewswire
29/07/2024

Philips delivers strong order intake growth in the second quarter, margin…

Second-quarter highlightsGroup sales amounted to EUR 4.5 billion, with comparable sales growth of 2%Comparable order intake increased by 9%Income from operations EUR 816 million, including EUR 538 million insurance income*)Adjusted EBITA margin increased to 11.1% of salesOperating cash inflow of EUR 89 million, with a free cash outflow of EUR 64 million Roy Jakobs, CEO of Royal Philips:“I am encouraged by our return to order intake growth this quarter, primarily driven by...
Nasdaq GlobeNewswire
29/07/2024

ALZHEIMER'S DISEASE BLOOD TESTS COULD IMPROVE DIAGNOSIS IN PRIMARY CARE, SPEED…

Dementia is often underdiagnosed—and if it is diagnosed by a clinician, many people nonetheless are unaware or uninformed of their diagnosis, according to the 2024 Alzheimer's Disease Facts and Figures report. Blood tests for Alzheimer's are demonstrating in research that they could significantly improve a clinician's accuracy and confidence, provide greater accessibility and a platform for enhanced communication. Dementia is often underdiagnosed—and if it is diagnosed by a clinician, many...
PR Newswire
28/07/2024

Innocan Pharma Submits Investigational New Animal Drug Application to FDA's…

The Company further announced that following the assessment of LPT-CBD's scientific package, the CVM recognized Innocan's contribution to pursuing innovative animal drug products and technology and granted the company a sponsor fee waiver for fiscal year 2024. Innocan's LPT-CBD is a proprietary drug delivery platform designed to provide prolonged-release CBD for chronic pain and well-being management in animals. Over the past year, repeated administration of LPT-CBD in dogs and...
PR Newswire
26/07/2024

EssilorLuxottica: Publication of the 2024 Interim Financial Report

Publication of the 2024 Interim Financial Report Paris, France(July 26, 2024 – 6:30 pm)– The Board of Directors of EssilorLuxottica met on July 25, 2024 to approve the condensed consolidated interim financial statements for the six-month period ended June 30, 2024.EssilorLuxottica's 2024 Interim Financial Report has been published today. The Interim Financial Report comprises the First-half 2024 Management Report, the Condensed Consolidated Interim Financial Statements, the...
Nasdaq GlobeNewswire
26/07/2024

Calliditas partner STADA receives European Commission decision for full approval…

"This is an important event for patients suffering from IgAN in Europe as Kinpeygo represents the first ever fully approved medication for this rare kidney disease. The long-term confirmatory trial met its eGFR endpoint with high statistical significance and we are delighted that the European Commission has granted a full approval for the broader population" said Renee Aguiar-Lucander, CEO. "This is an important event for patients suffering from IgAN inEuropeas Kinpeygo represents…
PR Newswire
26/07/2024

Junshi Biosciences Announces Positive Opinion from the European Medicines…

® ). The CHMP recommends approval for toripalimab for two indications:Toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma (NPC);Toripalimab in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (ESCC). The...
Nasdaq GlobeNewswire
26/07/2024

Genomics Personalized Health Market to reach US$ 33 Billion by 2034, Driven by…

The genomics personalized health market is rapidly evolving, fueled by cutting-edge technological advancements and an increasing focus on individualized healthcare. One of the key drivers of this market is the advent of next-generation sequencing (NGS) technologies, which have drastically reduced the cost and time required for sequencing the human genome. The genomics personalized health market is rapidly evolving, fueled by cutting-edge technological advancements and an increasing focus on...
PR Newswire
26/07/2024
Altri  Comunicati